REPRO-MED Systems (KRMD) AI Stock Analysis

• Market Cap: $185.86M
• Dividend Yield: N/A
• Average Volume (3M): 95.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 19.57%
• EPS Growth: 61.81%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 46,234,960
• 10 Day Avg. Volume: 111,461
• 30 Day Avg. Volume: 95,355
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 6.91
• Enterprise Value/Ebitda: -42.68
• 1Y Price Target: $5.00
• Price Target Upside: 26.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 59 Neutral
• Price Target: $4.50 ▲(13.92% Upside)

KRMD's overall score is driven by strong earnings call highlights and positive technical indicators, offset by weak financial performance and valuation concerns. The company's growth prospects are promising, but profitability and valuation issues remain significant risks.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates successful market penetration and product adoption, enhancing its competitive position and long-term sustainability.

International Expansion

Expanding international markets diversifies revenue streams and reduces reliance on domestic sales, supporting long-term growth and resilience against local market fluctuations.

Product Development

Advancements in product development enhance the company's innovation pipeline, ensuring future competitiveness and meeting evolving market needs.

Negative Factors

Gross Margin Decline

Declining gross margins can pressure profitability, indicating challenges in cost management that may affect long-term financial health if not addressed.

Domestic Inventory Reduction

Inventory reductions by key distributors could signal demand fluctuations, potentially impacting near-term revenue and requiring strategic adjustments.

Cash Flow Management

Negative cash flows highlight liquidity challenges, which can constrain operational flexibility and investment capacity, affecting long-term growth prospects.

REPRO-MED Systems Business Overview & Revenue Model

Company Description

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.

How the Company Makes Money

REPRO-MED Systems generates revenue through the sale of its medical devices, primarily the FREEDOM60 infusion system and its associated accessories. The company's revenue model is based on direct sales to healthcare providers, distributors, and patients, as well as potential recurring revenue from consumable products related to its infusion systems. Key revenue streams include the initial sale of infusion pumps and ongoing sales of disposable components that require regular replacement. Additionally, partnerships with healthcare organizations and networks can enhance distribution capabilities and broaden market access, contributing to the company's overall earnings.

REPRO-MED Systems Financial Statement Overview

Summary

REPRO-MED Systems is experiencing revenue growth, but consistent losses and negative cash flows pose significant challenges. While the balance sheet shows a stable equity base and manageable debt levels, the company must address its operational inefficiencies to improve profitability and cash generation. Strategic cost management and revenue enhancement are crucial for future financial health.

Income Statement

The company shows a consistent growth trajectory in revenue with a 5% increase from the previous period to TTM. However, it struggles with profitability as evidenced by negative EBIT and net profit margins, indicating operational inefficiencies and high costs relative to revenue. The gross profit margin remains healthy, suggesting some control over direct costs.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.22, indicating prudent leverage. However, the return on equity is negative due to consistent net losses, which is a concern. The equity ratio of 60% indicates a solid capital structure with more equity financing, providing some financial stability.

Cash Flow

Cash flow analysis reveals challenges, as the company has negative operating cash flow and free cash flow, indicating potential liquidity issues. The free cash flow growth rate improved slightly, but remains negative, highlighting ongoing cash management challenges. The operating cash flow to net income ratio is unfavorable due to persistent losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.85M	33.65M	28.52M	27.90M	23.49M	24.18M
Gross Profit	23.27M	21.33M	16.71M	15.37M	13.77M	14.94M
EBITDA	-3.77M	-5.56M	-9.40M	-10.19M	-6.57M	1.61M
Net Income	-4.52M	-6.07M	-13.74M	-8.66M	-4.56M	-1.21M
Balance Sheet
Total Assets	25.52M	27.22M	28.46M	42.33M	41.29M	39.92M
Cash, Cash Equivalents and Short-Term Investments	8.05M	9.58M	11.48M	17.41M	25.33M	27.32M
Total Debt	3.47M	3.99M	4.45M	4.93M	604.14K	239.49K
Total Liabilities	8.99M	10.40M	8.11M	11.01M	4.79M	3.76M
Stockholders Equity	16.53M	16.81M	20.35M	31.33M	36.50M	36.16M
Cash Flow
Free Cash Flow	-2.17M	-1.62M	-5.71M	-8.21M	-4.69M	-1.80M
Operating Cash Flow	-682.14K	-319.72K	-4.89M	-5.40M	-4.32M	-743.32K
Investing Cash Flow	-1.53M	-1.33M	-814.60K	-2.80M	-366.17K	-1.04M
Financing Cash Flow	-194.03K	-248.53K	-218.87K	279.49K	2.71M	23.22M

REPRO-MED Systems Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Neutral. The current price of 3.95 is below the 20-day moving average (MA) of 4.06, above the 50-day MA of 3.87, and above the 200-day MA of 3.50, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.14 is Neutral, neither overbought nor oversold. The STOCH value of 38.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KRMD.

REPRO-MED Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	77 Outperform	201.54M	16.85	11.81%	1.94%	-16.64%	-13.64%
INFU	70 Outperform	209.37M	43.21	9.30%	―	8.13%	1293.06%
KRMD	59 Neutral	$185.86M	―	-25.63%	―	19.57%	61.81%
RVP	51 Neutral	23.95M	-2.67	-11.43%	―	-0.24%	50.45%
MLSS	46 Neutral	37.12M	-5.44	-208.80%	―	7.84%	-43.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

REPRO-MED Systems Corporate Events

REPRO-MED Systems Holds Annual Shareholder Meeting

On May 14, 2025, REPRO-MED Systems held its Annual Meeting of Shareholders where key decisions were made regarding the company’s governance and financial oversight. Shareholders elected the proposed nominees to the board of directors, approved executive compensation on an advisory basis, and ratified the appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2025 fiscal year.

The most recent analyst rating on (KRMD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.